Blurbs

Analysts Are Bullish on These Healthcare Stocks: Aslan Pharmaceuticals (ASLN), Precision BioSciences (DTIL)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aslan Pharmaceuticals (ASLNResearch Report) and Precision BioSciences (DTILResearch Report) with bullish sentiments.

Aslan Pharmaceuticals (ASLN)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals, with a price target of $8.00. The company’s shares closed last Wednesday at $0.46, close to its 52-week low of $0.36.

According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.9% and a 32.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

Aslan Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.

See today’s best-performing stocks on TipRanks >>

Precision BioSciences (DTIL)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Precision BioSciences, with a price target of $20.00. The company’s shares closed last Wednesday at $1.49, close to its 52-week low of $1.11.

According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of -22.5% and a 27.5% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Milestone Pharmaceuticals, and Arrowhead Pharmaceuticals.

Currently, the analyst consensus on Precision BioSciences is a Strong Buy with an average price target of $12.75, implying a 738.8% upside from current levels. In a report issued on June 16, BMO Capital also initiated coverage with a Buy rating on the stock with a $7.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ASLN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos